Palbociclib Plus Letrozole Deemed Effective in Advanced Endometrial Cancer
Palbociclib plus letrozole prolonged PFS and maintained QoL compared with placebo plus letrozole, according to results from a phase 2 trial.
Gynecologic, Ovarian, and Cervical Cancer News
GYNECOLOGIC CANCER ADVISOR
American Cancer Society Updates Cervical Cancer Screening Guidelines
New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.
Clinically Significant Fatigue Common After Surgery for Gynecologic Cancers, Remains High 1 Year Later
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
PARP Inhibitors Deemed Too Costly For Across-the-Board Frontline Maintenance in Ovarian Cancer
Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.
Patient-Reported Outcomes for Rucaparib as a Maintenance Therapy in Recurrent Ovarian Cancer
Quality-adjusted progression-free survival (QA-PFS) represents an adjustment to PFS that incorporates patient-reported toxicity and other detrimental effects of treatment.
Study Finds Patients With Rare Ovarian Cancer Develop Chemoresistance
Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy.
ACS Issues Updated Guideline for Cervical Cancer Screening
Screening, preferably with primary HPV testing, should start at age 25 and continue through age 65.
Longitudinal MicroRNAs Lacked Predictive Value in Ovarian Cancer
Study results differ from prior research into microRNAs as predictive biomarkers.
Study Suggests QoL Assessments Do Not Support First-Line Combination Chemotherapy With Weekly Paclitaxel for Epithelial Ovarian Cancer
This analysis focused on QoL end points associated with different dosing schedules for first-line carboplatin-paclitaxel in a predominantly European population with EOC.
Radiotherapy for Cervical Cancer: An Introduction to ASTRO’s Clinical Practice Guideline
The consensus guideline, drafted by an ASTRO-convened expert task force, offers recommendations about radiotherapy, including brachytherapy, and chemoradiation, in different stage-of-disease and treatment-strategy settings.
Pap Tests May Hold Biomarkers Ahead of Ovarian Cancer Diagnosis
A proof-of-principle study confirms presence of TP53 variants ahead of diagnosis.
WEE1 Kinase Inhibitor Improved PFS in TP53-Mutated Ovarian Cancer
Preclinical studies of adavosertib indicated that the drug increased sensitization of TP53-mutated cells to chemotherapy.
Study Reveals Practice Gap for Patients Undergoing Endometrial Biopsy
The trajectory of follow-up care for women undergoing a failed endometrial biopsy has been largely unexplored.
TP53 Mutations Present in HPV-Negative Vulvar Cancer
In a whole-exome analysis, the most common mutations occurred in TP53, and mutations in other known cancer-associated genes were identified in women with HPV-negative vulvar cancer.
Uterus-Preserving Surgery May Be an Option for Ovarian Cancer Subtype
Women with Stage I primary mucinous epithelial ovarian carcinoma who underwent uterus-preserving surgery did not have worse survival, a retrospective study found.
Neoadjuvant Chemotherapy Increases Immunogenicity of High-Grade Serous Ovarian Cancer
This study sought to address outstanding questions regarding tumor heterogeneity in the setting of HGSOC, including its relationship with treatment response.
Birth Rates After ART Not Significantly Different Among Female Cancer Survivors, Siblings
The researchers found that patients who received pelvic radiation had a decreased chance of live birth.
KEYNOTE-100: Pembrolizumab Had Modest Activity in Recurrent Advanced Ovarian Cancer
Analysis of biomarkers to predict response to pembrolizumab are ongoing.
Olaparib/Cediranib Combination Is Not Superior to Standard of Care in Recurrent Ovarian Cancer
Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.
Secondary Cytoreductive Surgery Extended PFS in Recurrent Ovarian Cancer
A longer treatment-free survival interval associated with surgery may contribute to overall survival.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
